Claudio Orlando
Overview
Explore the profile of Claudio Orlando including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tosco A, Poli P, Casale A, De Gregorio F, Sepe A, Buonpensiero P, et al.
J Bronchology Interv Pulmonol
. 2022 Jun;
30(3):258-267.
PMID: 35698279
Background: Currently, no consensus guidelines recommend routine bronchoscopy procedure in cystic fibrosis (CF), as no evidence is available concerning its use as either a diagnostic or therapeutic tool. Its efficacy...
2.
Maglione M, Antonelli F, Orlando C
Pediatr Emerg Care
. 2022 Jun;
38(12):e1696-e1697.
PMID: 35686973
No abstract available.
3.
Malentacchi F, Vinci S, Melina A, Kuncova J, Villari D, Nesi G, et al.
Urol Oncol
. 2016 Mar;
34(7):292.e9-292.e16.
PMID: 27005925
Background: To identify molecular biomarkers for tumor diagnosis and monitoring of disease progression, several noninvasive tests on liquid biopsy have been proposed for different cancers including those of urogenital origin....
4.
Salvianti F, Orlando C, Massi D, De Giorgi V, Grazzini M, Pazzagli M, et al.
Front Mol Biosci
. 2016 Jan;
2:76.
PMID: 26779490
Solid tumor release into the circulation cell-free DNA (cfDNA) and circulating tumor cells (CTCs) which represent promising biomarkers for cancer diagnosis. Circulating tumor DNA may be studied in plasma from...
5.
Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli C, et al.
Clin Chem Lab Med
. 2015 Apr;
53(12):1935-42.
PMID: 25883202
Background: Circulating cell-free DNA (ccfDNA) has been confirmed as a useful biomarker in cancer and pre-natal clinical practice. One of the main critical points in using ccfDNA is a lack...
6.
Malentacchi F, Pazzagli M, Simi L, Orlando C, Wyrich R, Gunther K, et al.
PLoS One
. 2014 Nov;
9(11):e112293.
PMID: 25384019
One purpose of the EC funded project, SPIDIA, is to develop evidence-based quality guidelines for the pre-analytical handling of blood samples for RNA molecular testing. To this end, two pan-European...
7.
Pinzani P, Salvianti F, Orlando C, Pazzagli M
Methods Mol Biol
. 2014 Apr;
1160:133-45.
PMID: 24740228
This papers deals with the preanalytical and analytical phase of cell-free DNA analysis, highlighting some criticism on sample collection and extraction. We describe a method to accurately quantify total cfDNA...
8.
Massi D, Pinzani P, Simi L, Salvianti F, De Giorgi V, Pizzichetta M, et al.
Melanoma Res
. 2013 Aug;
23(5):414-9.
PMID: 23938765
The genotypic profile of rare amelanotic melanomas (AMs) has been poorly investigated, thus preventing either an accurate identification as a distinctive melanoma subtype or therapy stratification. Here, we investigated the...
9.
Galbiati S, Damin F, Pinzani P, Mancini I, Vinci S, Chiari M, et al.
PLoS One
. 2013 Mar;
8(3):e59939.
PMID: 23536897
Molecular diagnostics of human cancers may increase accuracy in prognosis, facilitate the selection of the optimal therapeutic regimen, improve patient outcome, reduce costs of treatment and favour development of personalized...
10.
Salvianti F, Pinzani P, Verderio P, Ciniselli C, Massi D, De Giorgi V, et al.
PLoS One
. 2012 Dec;
7(11):e49843.
PMID: 23209607
Cell-free DNA in blood (cfDNA) represents a promising biomarker for cancer diagnosis. Total cfDNA concentration showed a scarce discriminatory power between patients and controls. A higher specificity in cancer diagnosis...